Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

INTUITIVE SURGICAL INC Director's Dealing 2017

Oct 26, 2017

29809_dirs_2017-10-26_fec7f75a-7450-44bf-b971-f1cbef61f588.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: INTUITIVE SURGICAL INC (ISRG)
CIK: 0001035267
Period of Report: 2017-10-24

Reporting Person: RUBASH MARK J (Director)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2017-10-24 Common Stock M 3000 $123.7733 Acquired 6453 Direct
2017-10-24 Common Stock S 3000 $371.1707 Disposed 3453 Direct
2017-10-24 Common Stock M 3000 $193.08 Acquired 6453 Direct
2017-10-24 Common Stock S 3000 $371.1731 Disposed 3453 Direct
2017-10-24 Common Stock M 750 $119.0633 Acquired 4203 Direct
2017-10-24 Common Stock S 750 $371.1731 Disposed 3453 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2017-10-24 Non-Qualified Stock Option (right to buy) $119.0633 M 750 Disposed 2021-04-21 Common Stock (750) Direct
2017-10-24 Non-Qualified Stock Option (right to buy) $123.7733 M 3000 Disposed 2024-04-24 Common Stock (3000) Direct
2017-10-24 Non-Qualified Stock Option (right to buy) $193.08 M 3000 Disposed 2022-04-19 Common Stock (3000) Direct

Footnotes

F1: On October 6, 2017, the common stock and equity grants of Intuitive Surgical split 3-for-1, resulting in the reporting person's ownership of the company's stock and equity grants to increase (for every one share owned or granted, 2 additional shares were issued) and the exercise price of stock option grants to decrease to 1/3rd of the original grant price.

F2: These shares were sold pursuant to a Rule 10b5-1 Trading Plan, entered into on August 21, 2017.

F3: Non-statutory stock option granted pursuant to the Non-Employee Directors' Stock Option Plan. Option shall vest 100% one year after the date of grant or at the next Shareholders Meeting, whichever should take place first, provided that vesting will cease on termination of the Directors service to the Company.